Do analysts prefer ACTU or MTEX?

Actuate Therapeutics presently has a consensus target price of $17.50, suggesting a potential upside of 1,383.05%. Given Actuate Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Actuate Therapeutics is more favorable than Mannatech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Actuate Therapeutics 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Mannatech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer MTEX or ADXS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mannatech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Ayala Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts prefer ABVC or MTEX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ABVC BioPharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Mannatech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ABVC or MTEX more profitable?

ABVC BioPharma has a net margin of 0.00% compared to Mannatech's net margin of -11.97%. ABVC BioPharma's return on equity of -62.46% beat Mannatech's return on equity. Company Net Margins Return on Equity Return on Assets ABVC BioPharma N/A -62.46% -39.99% Mannatech -11.97% -2,383.34% -40.24%

Does the media favor ABVC or MTEX?

In the previous week, Mannatech had 2 more articles in the media than ABVC BioPharma. MarketBeat recorded 4 mentions for Mannatech and 2 mentions for ABVC BioPharma. ABVC BioPharma's average media sentiment score of 0.93 beat Mannatech's score of 0.64 indicating that ABVC BioPharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ABVC BioPharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mannatech 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate PYRGF or MTEX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PyroGenesis Canada 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Mannatech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate GOSS or MTEX?

Gossamer Bio currently has a consensus target price of $3.20, indicating a potential upside of 2,252.94%. Given Gossamer Bio's stronger consensus rating and higher possible upside, equities research analysts plainly believe Gossamer Bio is more favorable than Mannatech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gossamer Bio 2 Sell rating(s) 4 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.11 Mannatech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings and valuation, GOSS or MTEX?

Mannatech has higher revenue and earnings than Gossamer Bio. Mannatech is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Gossamer Bio $55.54M 0.57 -$170.37M -$0.79 N/A Mannatech $108.04M 0.08 -$15.21M -$6.71 N/A

Is GOSS or MTEX more profitable?

Mannatech has a net margin of -11.97% compared to Gossamer Bio's net margin of -324.82%. Gossamer Bio's return on equity of 0.00% beat Mannatech's return on equity. Company Net Margins Return on Equity Return on Assets Gossamer Bio -324.82% N/A -96.10% Mannatech -11.97% -2,383.34% -40.24%

Mannatech (MTEX) Competitors

$4.50 -0.16 (-3.43%)

As of 07/24/2026 03:32 PM Eastern

Compare

MTEX vs. ACTU, ADXS, ABVC, PYRGF, and GOSS

Should you buy Mannatech stock or one of its competitors? MarketBeat compares Mannatech with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Mannatech include Actuate Therapeutics (ACTU), Ayala Pharmaceuticals (ADXS), ABVC BioPharma (ABVC), PyroGenesis Canada (PYRGF), and Gossamer Bio (GOSS). These companies are all part of the "pharmaceutical products" industry.

How does Mannatech compare to Actuate Therapeutics?

Actuate Therapeutics (NASDAQ:ACTU) and Mannatech (NASDAQ:MTEX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, valuation, risk, dividends, analyst recommendations, institutional ownership and media sentiment.

13.0% of Mannatech shares are held by institutional investors. 58.0% of Actuate Therapeutics shares are held by company insiders. Comparatively, 47.5% of Mannatech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Actuate Therapeutics presently has a consensus target price of $17.50, suggesting a potential upside of 1,383.05%. Given Actuate Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Actuate Therapeutics is more favorable than Mannatech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Actuate Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Mannatech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Actuate Therapeutics has a net margin of 0.00% compared to Mannatech's net margin of -11.97%. Actuate Therapeutics' return on equity of -430.93% beat Mannatech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Actuate Therapeutics	N/A	-430.93%	-180.86%
Mannatech	-11.97%	-2,383.34%	-40.24%

In the previous week, Mannatech had 3 more articles in the media than Actuate Therapeutics. MarketBeat recorded 4 mentions for Mannatech and 1 mentions for Actuate Therapeutics. Actuate Therapeutics' average media sentiment score of 1.89 beat Mannatech's score of 0.64 indicating that Actuate Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Actuate Therapeutics	Very Positive
Mannatech	Positive

Actuate Therapeutics has a beta of 0.67, meaning that its share price is 33% less volatile than the broader market. Comparatively, Mannatech has a beta of 0.72, meaning that its share price is 28% less volatile than the broader market.

Mannatech has higher revenue and earnings than Actuate Therapeutics. Actuate Therapeutics is trading at a lower price-to-earnings ratio than Mannatech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Actuate Therapeutics	N/A	N/A	-$22.23M	-$0.97	N/A
Mannatech	$108.04M	0.08	-$15.21M	-$6.71	N/A

Summary

Actuate Therapeutics beats Mannatech on 8 of the 15 factors compared between the two stocks.

How does Mannatech compare to Ayala Pharmaceuticals?

Mannatech (NASDAQ:MTEX) and Ayala Pharmaceuticals (NASDAQ:ADXS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, earnings, analyst recommendations, risk, media sentiment and profitability.

Mannatech has higher revenue and earnings than Ayala Pharmaceuticals. Mannatech is trading at a lower price-to-earnings ratio than Ayala Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mannatech	$108.04M	0.08	-$15.21M	-$6.71	N/A
Ayala Pharmaceuticals	$3.24M	11.05	-$48.07M	-$5.02	N/A

Mannatech has a beta of 0.72, suggesting that its share price is 28% less volatile than the broader market. Comparatively, Ayala Pharmaceuticals has a beta of 1.75, suggesting that its share price is 75% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mannatech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Ayala Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

13.0% of Mannatech shares are owned by institutional investors. Comparatively, 7.2% of Ayala Pharmaceuticals shares are owned by institutional investors. 47.5% of Mannatech shares are owned by insiders. Comparatively, 0.6% of Ayala Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Ayala Pharmaceuticals has a net margin of 0.00% compared to Mannatech's net margin of -11.97%. Ayala Pharmaceuticals' return on equity of 0.00% beat Mannatech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mannatech	-11.97%	-2,383.34%	-40.24%
Ayala Pharmaceuticals	N/A	N/A	N/A

In the previous week, Mannatech had 4 more articles in the media than Ayala Pharmaceuticals. MarketBeat recorded 4 mentions for Mannatech and 0 mentions for Ayala Pharmaceuticals. Mannatech's average media sentiment score of 0.64 beat Ayala Pharmaceuticals' score of 0.00 indicating that Mannatech is being referred to more favorably in the media.

Company	Overall Sentiment
Mannatech	Positive
Ayala Pharmaceuticals	Neutral

Summary

Mannatech and Ayala Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks.

How does Mannatech compare to ABVC BioPharma?

ABVC BioPharma (NASDAQ:ABVC) and Mannatech (NASDAQ:MTEX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, risk, earnings, dividends, valuation, analyst recommendations, institutional ownership and media sentiment.

11.4% of ABVC BioPharma shares are held by institutional investors. Comparatively, 13.0% of Mannatech shares are held by institutional investors. 19.0% of ABVC BioPharma shares are held by company insiders. Comparatively, 47.5% of Mannatech shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

ABVC BioPharma has higher earnings, but lower revenue than Mannatech. ABVC BioPharma is trading at a lower price-to-earnings ratio than Mannatech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ABVC BioPharma	N/A	N/A	-$7.91M	-$0.40	N/A
Mannatech	$108.04M	0.08	-$15.21M	-$6.71	N/A

ABVC BioPharma has a beta of 0.54, meaning that its stock price is 46% less volatile than the broader market. Comparatively, Mannatech has a beta of 0.72, meaning that its stock price is 28% less volatile than the broader market.

ABVC BioPharma has a net margin of 0.00% compared to Mannatech's net margin of -11.97%. ABVC BioPharma's return on equity of -62.46% beat Mannatech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ABVC BioPharma	N/A	-62.46%	-39.99%
Mannatech	-11.97%	-2,383.34%	-40.24%

In the previous week, Mannatech had 2 more articles in the media than ABVC BioPharma. MarketBeat recorded 4 mentions for Mannatech and 2 mentions for ABVC BioPharma. ABVC BioPharma's average media sentiment score of 0.93 beat Mannatech's score of 0.64 indicating that ABVC BioPharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ABVC BioPharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mannatech	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ABVC BioPharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Mannatech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

ABVC BioPharma and Mannatech tied by winning 6 of the 12 factors compared between the two stocks.

How does Mannatech compare to PyroGenesis Canada?

PyroGenesis Canada (NASDAQ:PYRGF) and Mannatech (NASDAQ:MTEX) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, valuation, profitability and media sentiment.

Mannatech has higher revenue and earnings than PyroGenesis Canada. PyroGenesis Canada is trading at a lower price-to-earnings ratio than Mannatech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PyroGenesis Canada	$9.14M	3.56	-$21.12M	-$0.04	N/A
Mannatech	$108.04M	0.08	-$15.21M	-$6.71	N/A

PyroGenesis Canada has a beta of 0.24, suggesting that its stock price is 76% less volatile than the broader market. Comparatively, Mannatech has a beta of 0.72, suggesting that its stock price is 28% less volatile than the broader market.

0.0% of PyroGenesis Canada shares are owned by institutional investors. Comparatively, 13.0% of Mannatech shares are owned by institutional investors. 47.7% of PyroGenesis Canada shares are owned by insiders. Comparatively, 47.5% of Mannatech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Mannatech had 4 more articles in the media than PyroGenesis Canada. MarketBeat recorded 4 mentions for Mannatech and 0 mentions for PyroGenesis Canada. Mannatech's average media sentiment score of 0.64 beat PyroGenesis Canada's score of 0.00 indicating that Mannatech is being referred to more favorably in the news media.

Company	Overall Sentiment
PyroGenesis Canada	Neutral
Mannatech	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PyroGenesis Canada	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Mannatech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Mannatech has a net margin of -11.97% compared to PyroGenesis Canada's net margin of -115.14%. PyroGenesis Canada's return on equity of 0.00% beat Mannatech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PyroGenesis Canada	-115.14%	N/A	-60.81%
Mannatech	-11.97%	-2,383.34%	-40.24%

Summary

Mannatech beats PyroGenesis Canada on 10 of the 14 factors compared between the two stocks.

How does Mannatech compare to Gossamer Bio?

Gossamer Bio (NASDAQ:GOSS) and Mannatech (NASDAQ:MTEX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, profitability, earnings, risk, media sentiment, institutional ownership and valuation.

In the previous week, Mannatech had 3 more articles in the media than Gossamer Bio. MarketBeat recorded 4 mentions for Mannatech and 1 mentions for Gossamer Bio. Gossamer Bio's average media sentiment score of 1.87 beat Mannatech's score of 0.64 indicating that Gossamer Bio is being referred to more favorably in the media.

Company	Overall Sentiment
Gossamer Bio	Very Positive
Mannatech	Positive

Mannatech has a net margin of -11.97% compared to Gossamer Bio's net margin of -324.82%. Gossamer Bio's return on equity of 0.00% beat Mannatech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gossamer Bio	-324.82%	N/A	-96.10%
Mannatech	-11.97%	-2,383.34%	-40.24%

Mannatech has higher revenue and earnings than Gossamer Bio. Mannatech is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gossamer Bio	$55.54M	0.57	-$170.37M	-$0.79	N/A
Mannatech	$108.04M	0.08	-$15.21M	-$6.71	N/A

Gossamer Bio has a beta of 2.04, suggesting that its stock price is 104% more volatile than the broader market. Comparatively, Mannatech has a beta of 0.72, suggesting that its stock price is 28% less volatile than the broader market.

Gossamer Bio currently has a consensus target price of $3.20, indicating a potential upside of 2,252.94%. Given Gossamer Bio's stronger consensus rating and higher possible upside, equities research analysts plainly believe Gossamer Bio is more favorable than Mannatech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gossamer Bio	2 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.11
Mannatech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

81.2% of Gossamer Bio shares are held by institutional investors. Comparatively, 13.0% of Mannatech shares are held by institutional investors. 3.7% of Gossamer Bio shares are held by company insiders. Comparatively, 47.5% of Mannatech shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Gossamer Bio beats Mannatech on 10 of the 16 factors compared between the two stocks.

Get Mannatech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MTEX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MTEX vs. The Competition

Export

Metric	Mannatech	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$8.99M	$3.08B	$6.87B	$12.26B
Dividend Yield	N/A	2.07%	2.67%	9.79%
P/E Ratio	-0.67	20.29	27.11	23.64
Price / Sales	0.08	485.19	517.09	89.57
Price / Cash	N/A	27.62	50.54	59.64
Price / Book	-1.64	4.13	10.28	6.07
Net Income	-$15.21M	$65.94M	$3.60B	$331.99M
7 Day Performance	5.88%	-4.16%	-1.27%	-0.63%
1 Month Performance	-10.54%	-3.76%	-0.37%	-2.00%
1 Year Performance	-44.13%	9.94%	18.30%	13.62%

Mannatech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MTEX Mannatech	1.1073 of 5 stars	$4.50 -3.4%	N/A	-44.5%	$8.99M	$108.04M	N/A	250	News Coverage Positive News Gap Down
ACTU Actuate Therapeutics	2.6342 of 5 stars	$1.73 +15.3%	$17.50 +911.6%	-83.1%	$35.89M	N/A	N/A	10	Positive News Gap Down High Trading Volume
ADXS Ayala Pharmaceuticals	N/A	$0.60 flat	N/A	N/A	$35.79M	$3.24M	N/A	20
ABVC ABVC BioPharma	0.508 of 5 stars	$1.34 -0.7%	N/A	-64.6%	$35.10M	$510K	N/A	30
PYRGF PyroGenesis Canada	N/A	$0.14 -4.9%	N/A	-55.6%	$34.81M	$9.14M	N/A	90	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MTEX) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Mannatech (MTEX) Competitors

MTEX vs. ACTU, ADXS, ABVC, PYRGF, and GOSS

How does Mannatech compare to Actuate Therapeutics?

Summary

How does Mannatech compare to Ayala Pharmaceuticals?

Summary

How does Mannatech compare to ABVC BioPharma?

Summary

How does Mannatech compare to PyroGenesis Canada?

Summary

How does Mannatech compare to Gossamer Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MTEX vs. The Competition

Mannatech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Mannatech (MTEX) Competitors

MTEX vs. ACTU, ADXS, ABVC, PYRGF, and GOSS

How does Mannatech compare to Actuate Therapeutics?

Do institutionals and insiders hold more shares of ACTU or MTEX?

Do analysts prefer ACTU or MTEX?

Is ACTU or MTEX more profitable?

Does the media prefer ACTU or MTEX?

Which has more volatility and risk, ACTU or MTEX?

Which has higher earnings & valuation, ACTU or MTEX?

Summary

How does Mannatech compare to Ayala Pharmaceuticals?

Which has higher valuation & earnings, MTEX or ADXS?

Which has more volatility & risk, MTEX or ADXS?

Do analysts prefer MTEX or ADXS?

Do institutionals & insiders have more ownership in MTEX or ADXS?

Is MTEX or ADXS more profitable?

Does the media refer more to MTEX or ADXS?

Summary

How does Mannatech compare to ABVC BioPharma?

Do insiders & institutionals hold more shares of ABVC or MTEX?

Which has stronger valuation and earnings, ABVC or MTEX?

Which has more risk and volatility, ABVC or MTEX?

Is ABVC or MTEX more profitable?

Does the media favor ABVC or MTEX?

Do analysts prefer ABVC or MTEX?

Summary

How does Mannatech compare to PyroGenesis Canada?

Which has stronger valuation and earnings, PYRGF or MTEX?

Which has more risk & volatility, PYRGF or MTEX?

Do insiders and institutionals hold more shares of PYRGF or MTEX?

Does the media prefer PYRGF or MTEX?

Do analysts rate PYRGF or MTEX?

Is PYRGF or MTEX more profitable?

Summary

How does Mannatech compare to Gossamer Bio?

Does the media prefer GOSS or MTEX?

Is GOSS or MTEX more profitable?

Which has stronger earnings and valuation, GOSS or MTEX?

Which has more risk & volatility, GOSS or MTEX?

Do analysts rate GOSS or MTEX?

Do institutionals & insiders believe in GOSS or MTEX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MTEX vs. The Competition

Mannatech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools